NCT06188468View on ClinicalTrials.gov

ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Solid Tumors

NACompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

October 1, 2023

Primary Completion Date

August 31, 2024

Study Completion Date

August 31, 2024

Conditions
TumorSolid TumorPositron-Emission Tomography
Interventions
DIAGNOSTIC_TEST

standard-of-care imaging (18F-FDG, 68Ga-PSMA, or 68Ga-DOTATATE PET/CT), 68Ga-MY6349 PET/CT

Each subject receives a single intravenous injection of standard-of-care imaging radiopharmaceuticals (18F-FDG, 68Ga-PSMA, or 68Ga-DOTATATE) and 68Ga-MY6349, and undergoes PET/CT imaging within the specified time.

Trial Locations (1)

361003

The First Affiliated Hospital of Xiamen University, Xiamen

All Listed Sponsors
lead

The First Affiliated Hospital of Xiamen University

OTHER

NCT06188468 - ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Solid Tumors | Biotech Hunter | Biotech Hunter